The 2-Minute Rule for Milademetan
All enrolled individuals who acquired at the least a person dose of zosuquidar or placebo through induction were monitored to the incidence of adverse gatherings (439 people, 219 on zosuquidar and 210 on placebo). The commonest adverse occasions had been relevant to the duration of prolonged and important myelosuppression as is expected with induct